|
 
> Follow the talks
here |

Contents
Prologue
back to top
Doha Ministerial Conference
9–14 November 2001
back to top
-
The Doha Ministerial Declaration adopted 14 November 2001,
WT/MIN(01)/DEC/1
-
Ministerial Declaration on the TRIPS Agreement and Public Health adopted 14 November 2001, WT/MIN(01)/DEC/2
-
Ministerial Decision on Implementation-Related Issues and Concerns decided 14 November 2001, WT/MIN(01)/17
-
Ministerial Decision on the Waiver for the EU-ACP Partnership
Agreement decided 14 November 2001, WT/MIN(01)/15
-
Ministerial Decision on the EU’s Transitional Regime for Banana
Imports decided 14 November 2001, WT/MIN(01)/16
-
Subsidies and Countervailing Measures Committee — Procedures for
extending provisions allowing some developing countries to continue to
subsidize exports, adopted 14 November 2001,
G/SCM/39.
(This comes under paragraph 10.6 of the Doha Implementation Decision,
and refers to Article 27.4 of the Subsidies Agreement. The procedure
is issued by the Subsidies and Countervailing Measures Committee,
which met specially for the purpose at the Doha Ministerial
Conference. The decision was adopted on 14 November 2001, along with
the Doha ministerial declarations and decisions.)
Organization of work Geneva 2002
back to top
Doha Round texts after Doha
back to top
TRIPS and public health 2002, 2003
back to top
-
TRIPS Council decision allowing
least-developed countries until 2016 to protect pharmaceutical patents
and test data
decided 1 July 2002, IP/C/25
(A few days after this was agreed in the TRIPS Council, the General
Council reached a closely related decision on 8 July 2002 (WT/L/478),
allowing least-developed countries until 2016 to grant exclusive
marketing rights under Article 70.9 of the TRIPS Agreement. This deals
with the situation where pharmaceutical patents are not protected, but
a patent application has been submitted and the government has allowed
the product to be marketed.)
-
General Council decision on compulsory licensing for export
(“Implementation of paragraph 6 of the Doha Declaration on the TRIPS
Agreement and public health”)
decided 30 August 2003, WT/L/540 and Corr.1
(The General Council has adopted two decisions on the “Paragraph 6”
system — a reference to Paragraph 6 of the Doha Ministerial
Declaration on TRIPS and Public Health. The decisions dealt with an
obstacle for countries needing to import cheaper generics made under
compulsory licensing when they were unable to manufacture the
medicines themselves. Now, pharmaceutical products can be made under
compulsory licence in one country, exclusively for exporting to
another country which lacks its own production capacity, provided
certain conditions are met.
The first decision, adopted in 2003 just before the Cancún Ministerial
Conference, is reproduced here. It is the one that is currently in
force, a waiver bypassing provisions of Articles 31(f) and 31 (h) of
the TRIPS Agreement. The second (General Council decision WT/L/641)
was adopted in 2005 on the eve of the Hong Kong Ministerial
Conference. It will replace the waiver with a permanent amendment
whose contents are identical, when two thirds of the WTO’s members
have accepted the change.
When the waiver and the proposed amendment were adopted, the General
Council chairperson also read out a statement, which can be found on
the WTO website, along with other information on the subject,
here)
|

|